Peter C. Black and Gregory J. Mize contributed equally to the study.
Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer†
Article first published online: 20 MAR 2007
Copyright © 2007 Wiley-Liss, Inc.
Volume 67, Issue 7, pages 743–756, 15 May 2007
How to Cite
Black, P. C., Mize, G. J., Karlin, P., Greenberg, D. L., Hawley, S. J., True, L. D., Vessella, R. L. and Takayama, T. K. (2007), Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate, 67: 743–756. doi: 10.1002/pros.20503
- Issue published online: 28 MAR 2007
- Article first published online: 20 MAR 2007
- Manuscript Accepted: 12 JUL 2006
- Manuscript Received: 16 MAY 2006
- Department of Defense. Grant Number: DAMD17-03-01-0039
- National Institutes of Health. Grant Number: HL16919
- SMT Foundation
- prostate cancer
Although protease-activated receptors (PARs) have been described to play a role in different malignancies, their expression and biological activity in prostate cancer are mostly unknown.
PAR expression in radical prostatectomy specimens was investigated by immunohistochemistry (IHC, 40 patients) and RT-PCR. Their role in LNCaP prostate cancer cell migration and Rac1/Cdc42 signaling was assessed with Boyden chamber analysis and Western blot, respectively.
PAR mRNA expression was higher in cancer, and protein expression was increased in PAR-1 (45%), PAR-2 (42%), and PAR-4 (68%), compared to normal glands. Increased PAR-1 (periglandular stroma) was associated with higher rates of biochemical recurrence (median follow-up, 5 years; P = 0.006). LNCaP migration was enhanced twofold and Rac1/Cdc42 signaling was activated by stimulation of PAR-1 and PAR-2.
PARs are overexpressed in prostate cancer and may serve as potential predictors of recurrence. The data suggest potential role of PARs in autocrine and paracrine mechanisms of prostate cancer. Prostate 67: 743–756, 2007. © 2007 Wiley-Liss, Inc.